Feed GIFOF
GI

Grifols, S.A. GIFOF OTC · Healthcare · Spain

$7.29 +0.00% +$0.00

Summary

58 / 100 · Bulios Score

What speaks for it

  • Earnings per share grew by 24% a year over the last 3 years.
  • The share price is below the Bulios Fair Price.

What to watch

  • Repaying its net debt would take 4.9 years of operating profit.
  • It missed profit estimates 6 times in the last 8 quarters.
  • It earns only 5.5 EUR a year on every 100 EUR of invested capital.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap
Bulios Fair Price
Undervalued Price today $7.29

By our assumptions the business is worth more than its shares cost today.

P/E today 13.4 67% lower
5-year average P/E 41.0
P/E today 13.4
Drug Manufacturers - General industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 13.4 EUR for 1 EUR of yearly profit. Over the last five years it was 41.0 EUR on average.

Valuation in detail

Is it growing?

Slowly

Revenue (EUR)

Diluted EPS (EUR)

  • Analyst estimate

Revenue grew by 7.1% a year over 5 years. Over the last 3 years it grew by 7.4% a year. For the next fiscal year analysts expect revenue to grow by 0.6%. Earnings per share grew by 24% a year over the last 3 years.

Growth in detail

Does it make money?

Reasonably

Where 100 EUR of revenue goes

Net profit, industry median (Drug Manufacturers - General) 14 EUR

Out of every 100 EUR of revenue, 6.4 EUR is left as net profit.

Profitability in detail

Is it financially healthy?

Debt is a burden

Repaying all its debt would take 12.3 years of free cash flow. Its debt is larger than its cash.

Financial health in detail

Does it pay a dividend?

Small, safe
Yield
1.45%
Paid out of profit
19%

The company covers the payout with ease.

Dividends in detail

What do analysts expect?

Mildly positive

No analyst has published a price target.

57% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2025

By product

By region

Haemoderivatives brings in 86% of revenue. Other Product grew fastest, by 9.3% a year.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy